Marshall Wace, LLP Annovis Bio, Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$5.55 - $19.62 $180,830 - $639,258
32,582 New
32,582 $609,000
Q1 2022

May 16, 2022
SELL
$11.84 - $19.78 $19,879 - $33,210
-1,679 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$17.58 - $37.67 $29,516 - $63,247
1,679 New
1,679 $29,000

Others Institutions Holding ANVS

# of Institutions
46
Shares Held
1.17M
Call Options Held
229K
Put Options Held
934K
View Full List

About Annovis Bio, Inc.

ANVS Quotes by TradingView
  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $46.2M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email